A GLOBAL PHASE 3, RANDOMIZED, OPEN-LABEL, MULTI-CENTER TRIAL DESIGNED TO COMPARE EFFIACY AND SAFETY OF LISOCABTAGENE MARALEUCEL VS INVESTIGATOR¿S CHOICE OPTIONS (IDEALISIB+RITUXIMAB OR BENDAMUSTINE +RITUXIMAB) IN ADULT PARTICIPANTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WHOSE DISEASE HAS FAILED TREATMENT WITH BOTH BTKI AND BCL2I TARGETED THERAPIES (A DOUBLE CLASS EXPOSED POPULATION) (CA0821170)